Valion Bio Accepts Resignation of CEO and Elects New Director

Valion Bio Inc. (VBIO) disclosed that its chief executive officer has resigned and that a new director has been elected to the board, according to an 8-K filed with the SEC on June 3, 2026.

The filing covers Item 5.02 on the departure and election of directors and principal officers, Item 5.07 on the submission of matters to a vote of security holders, and Item 9.01 on financial statements and exhibits. Item 5.02 requires the company to identify the named individual, the role involved, whether the action is a departure or election, the effective date, and any cited cause.

The resignation removes the CEO from day-to-day executive leadership of the clinical-stage biotechnology company. A new board member now holds a seat, shifting the composition of the body that oversees corporate strategy, compensation, and compliance. Both changes take effect on the dates stated in the filing.

Operationally the company must now operate without its former chief executive until a permanent successor is named or an interim leader is designated. The board, with its altered membership, assumes direct responsibility for that succession process.

The filing itself starts the clock on any related Form 4 or Form 8-K amendments that public companies must submit within two business days of director or officer transactions under SEC rules. Future proxy statements will reflect the updated board composition for the next annual shareholder meeting.

Downstream the leadership transition requires Valion Bio to maintain uninterrupted compliance with Nasdaq listing standards on board independence and audit-committee composition. Any executive-compensation arrangements tied to the former CEO, including severance, must be disclosed in subsequent filings.

The election of the new director also resets certain insider-trading blackout periods and short-swing profit rules under Section 16 for that individual.

This 8-K constitutes the company's official notification to investors of the governance change. Valion Bio, CIK 0001787740, last appeared in SEC records prior to this filing with no watchlist status. The Form 8-K supplies the primary legal record; no separate press release or explanatory narrative was appended beyond the standard Item disclosures.